TLS manipulation and immunotherapy in pancreatic cancer face significant mechanistic and regulatory uncertainties

Photo by Steve A Johnson / Unsplash

Frontiers in Medicine Published May 29, 2026 Medically reviewed May 29, 2026 Study authors: Yimin Chen, Yi Xiao, Taochun Zhang, Xinbo Wang DOI ↗ By Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease

Key Takeaway

Note limited mechanistic understanding and regulatory uncertainty regarding TLS manipulation in pancreatic cancer.

This narrative review addresses the role of TLS manipulation and immunotherapy in the context of pancreatic cancer. The scope covers the current state of knowledge regarding these interventions for this specific condition. The authors highlight that a limited mechanistic understanding exists regarding how specific components of TLS contribute to clinical outcomes. Furthermore, the temporal dynamics governing TLS induction, maturation, maintenance, and resolution remain poorly elucidated in the literature. Uncertainty also pertains to the precise regulatory pathways that modulate TLS function within the immunosuppressive tumor microenvironment. These gaps suggest that the field requires further investigation before definitive clinical recommendations can be made. The review does not report specific adverse events, sample sizes, or primary outcomes for the interventions discussed. Consequently, the practice relevance remains undefined by quantitative data in this source. Clinicians should interpret these findings as qualitative observations rather than established evidence. The lack of reported safety data and outcome metrics limits the immediate applicability of these concepts to routine practice. Future research must address these mechanistic and regulatory gaps to advance therapeutic strategies.

Study Details

Study typeSystematic review

EvidenceLevel 1

PublishedMay 2026

View Original Abstract ↓

Pancreatic cancer is a highly malignant neoplasm with a poor prognosis. The low immunogenicity of the tumor, strong immunosuppression in the tumor microenvironment (TME), and a dense tumor stroma contribute to this outcome. As a result, it is crucial to remodel the pancreatic cancer immune microenvironment to turn “cold” tumors into “hot” ones. The presence of tertiary lymphoid structures (TLS) in the TME is linked to improved prognosis and better patient outcomes. Nevertheless, the complexity of TLS biology presents several critical research gaps. Foremost, among these is the limited mechanistic understanding of how specific components of TLS--such as distinct immune cell subsets, stromal elements and their molecular interactions contribute to either beneficial or adverse clinical outcomes. Furthermore, the temporal dynamics governing TLS induction, maturation, maintenance, and resolution in response to different therapeutic modalities remain poorly elucidated. Another significant area of uncertainty pertains to the precise regulatory pathways that modulate TLS function within the immunosuppressive tumor microenvironment of pancreatic cancer. The classical maturation model of TLS describes a linear development. Based on recent advances in the evolution of TLS, we propose the concept of TLS life cycle in this review which included the tissue-resident memory phase. The mechanisms that direct TLS induction, maturation, maintenance, and resolution after various therapies are then addressed. We also discuss the identification and detection of TLS and elaborate on TLS prognostic value. We synthesize in detail the relationship between TLS and the response to therapy in PDAC. Finally, we present some preclinical evidence favoring the manipulation of TLS function and evolution within the immunosuppressive tumor microenvironment of PDAC.